Dupilumab May be A Promising Treatment Option For Bullous Pemphigoid

Dupilumab (Dupixent) showed promise as a potential treatment options for patients with bullous pemphigoid, according to a recent case series. The case series found that the majority of patients experienced some form of disease improvement or reported satisfactory response following treatment with the IL-4Rα blocker.

“Bullous pemphigoid is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments,” the authors said. They assessed treatment outcomes of dupilumab among 13 patients with bullous pemphigoid treated at 5 academic centers (average age 76.8 years). The average duration of bullous pemphigoid prior to initiating dupilumab was 28.8 months. Satisfactory response to treatment was defined as clinician documentation of disease improvement and patient desire to remain on medication without documentation of disease clearance.
_______________________________________________________________________
You may also like...

International Consensus on Pemphigus Diagnosis and Treatment Published
Pemphigus and Pemphigoid Associated With Comorbid Autoimmune Disorders
Subgroup of Patients with BP Have Mucosal Involvement
_______________________________________________________________________

Overall, 12 of 13 patients (92.3%) achieved either disease clearance or satisfactory response, the authors said. Total clearance of bullous pemphigoid was achieved in 7 patients (53.8%). In addition, no adverse events were reported, they added.

“Dupilumab may be an additional treatment for bullous pemphigoid, leading to disease clearance or satisfactory response in 92.3% of patients including in those who previously failed conventional therapy,” the authors concluded.

Reference

Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series [published online March 13, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.01.089